The dysregulated Type 2 immune response drives AD


Three types of immune response play a natural protective role against different pathogens, the Type 2 immune response drives AD specifically2-4

Type 2 inflammation, due to increased signalling of IL-4 and IL-13, contributes to the clinical disease features of AD4–6



Dysregulation of the Type 2 immune response5,7


Leads to increased signalling and production of IL-4 and IL-135


Which drives and perpetuates Type 2 inflammation5


Resulting in the clinical disease features of AD:4,6

•  Skin barrier dysfunction
•  Skin lesions
•  Itch
•  Increased susceptibility to skin infections

 

Selectively targeting a single signalling receptor, the IL-4Rα, thereby inhibiting IL-4 and IL-13 signalling, can help to reduce the persistent underlying Type 2 inflammation in AD8

Learn more about the pathophysiology of AD


Inflammatory pathways

What are the main inflammatory pathways involved in the disease? Find out about the pathway involved in AD.



Find out more


Overview of AD

Find out more about how AD has a continuous inflamation cycle.




Find out more


Mode of action DUPIXENT

Have questions about how DUPIXENT works?





Find out more

    AD, atopic dermatitis; IL, interleukin; IL-4Rα, interleukin 4 receptor alpha; ILC, innate lymphoid cells; Th, T-helper cells.

    References

    1. DUPIXENT Summary of Product Characteristics. September 2021.
    2. Leung DYM, et al. J Clin Invest. 2004;113(5):651–657.
    3. Suárez-Fariñas M, et al. J Allergy Clin Immunol. 2011;127(4):954–964.
    4. Gittler JK, et al. J Allergy Clin Immunol. 2012;130(6):1344–1354.
    5. Gandhi NA, et al. Nat Rev Drug Discov. 2016;15:35–50.
    6. Biedermann T, et al. Front Immunol. 2015;6:353.
    7. Artis D & Spits H. Nature. 2015;517:293–301.
    8. Guttman-Yassky E, et al. J Allergy Clin Immunol. 2019;143:155– 172.

MAT-IE-2101040(v4.0) | Date of preparation: February 2022